In vitro antioxidant properties of pentoxifylline and vinpocetine in a rheological model.
Horvath
Beata
B
Vekasi
Judit
J
Kesmarky
Gabor
G
Toth
Kalman
K
D000328:Adult; D001809:Blood Viscosity / Q000187:drug effects; D002110:Caffeine / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000037:antagonists & inhibitors; D004533:Egtazic Acid / Q000494:pharmacology; D004903:Erythrocyte Aggregation / Q000187:drug effects; D016166:Free Radical Scavengers / Q000494:pharmacology*; D018056:Hemorheology / Q000187:drug effects*; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000494:pharmacology; D010208:Papaverine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010431:Pentoxifylline / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology; D014748:Vinca Alkaloids / Q000494:pharmacology*
D016166:Free Radical Scavengers; D010726:Phosphodiesterase Inhibitors; D014748:Vinca Alkaloids; D000001:Calcimycin; D002110:Caffeine; D004533:Egtazic Acid; C013983:vinpocetine; C005317:drotaverin; D014700:Verapamil; D010208:Papaverine; D009543:Nifedipine; D010431:Pentoxifylline; D002118:Calcium